Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Gilead’s Blockbuster Sovaldi Linked to Slower Heartbeats and Puts Patients at Risk of Passing Out

NEW YORK – A team of French doctors reported Gilead Sciences, Inc. (GILD)’s blockbuster hepatitis C drug Sovaldi can cause abnormally slower heart rates in patients taking the medication. The slower heartbeats can cause patients to pass out, the doctors said in a letter to The New England Journal of Medicine. According to the French […]

Read More »

Gilead hepatitis C drug sales trend flattens, shares dip

Gilead Sciences Inc on Tuesday said its quarterly profit rose 70 percent, but sales growth for its hepatitis C drugs flattened as health insurers limited access to the expensive treatments. Shares of the biotechnology company fell slightly. Gilead’s quarterly product sales rose 37 percent to $8.2 billion. Sales of hepatitis C drugs Sovaldi and Harvoni […]

Read More »

Drug industry must address image problem over prices: Teva executive

Teva Pharmaceutical Industries Ltd’s research chief said on Tuesday the drug industry must act responsibly when it comes to pricing medications, given the mounting anger over the high cost of therapies in the United States.   Democratic presidential candidate Hillary Clinton brought new attention to the issue last week, proposing to cap patients’ treatment costs, […]

Read More »

Gilead combo drug fights all forms of hep C infection: data

Gilead Sciences Inc said its experimental combination treatment was effective against all forms of hepatitis C infection, citing data from four late-stage studies. The trials were evaluating a once-daily, fixed-dose combination of the drugmaker’s hep C drug, Sovaldi, with velpatasvir, an experimental NS5A inhibitor. The main goal of each study was to achieve a cure, […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!

Subscribe

Ad Right Bottom